A carregar...
Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma
Sorafenib is an inhibitor of multiple kinases that has demonstrated antiproliferative and antiangiogenic activity in a number of in vitro and in vivo model systems. A phase I study was conducted to determine the maximum tolerated dose (MTD) of sorafenib in patients with recurrent malignant glioma. S...
Na minha lista:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3223097/ https://ncbi.nlm.nih.gov/pubmed/21954442 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nor145 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|